FDA Approves Revumenib for Relapsed or Refractory Acute Leukaemia with a KMT2A Translocation By Ogkologos - December 10, 2024 98 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the AUGMENT-101 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Nivolumab and Ipilimumab to Unresectable or Advanced HCC ESMO Sarcoma and Rare Cancers Congress 2025, Lugano, Switzerland, 20-22 March New on NCI’s Websites for March 2025 MOST POPULAR Intensive care nurse describes his experience of female-centred care after breast... February 7, 2023 President’s Cancer Panel Report: Closing Gaps in Cancer Screening for All... February 3, 2022 Presence of Intratumoural TLSs in Advanced STS as a Potential Predictive... June 7, 2022 Husband Moved To Tears After Opening Christmas Gift From Wife December 31, 2021 Load more HOT NEWS Glucose Control Key in Reducing Cancer Risk for People with Type... ESMO-WHO Collaboration in Kazakhstan Yields Evidence-Based Approach for Closing the Gaps... Fostering Growth and Creativity Through Journaling Could a Vaccine Prevent Colorectal Cancer in People with Lynch Syndrome?
